Back to HomeKorea StockPremiumAll HanAll Biopharma coverageHanall Biopharma (009420.KS) Q1 2026: Operating Loss Flips to ₩840M Profit as Clinical Debt Surges 79%Jul 2, 2026By MinJeKimShareRead in:English한국어日本語繁體中文
